Show simple item record

dc.contributor.authorKaradeniz, Sedat Tanjuen_US
dc.contributor.authorAkgul, Sebahat Ustaen_US
dc.contributor.authorOgret, Yelizen_US
dc.contributor.authorCiftci, Hayriye Senturken_US
dc.contributor.authorBayraktar, Ademen_US
dc.contributor.authorBakkaloglu, Hüseyinen_US
dc.contributor.authorCaliskan, Yasar Keremen_US
dc.contributor.authorYelekçi, Kemalen_US
dc.contributor.authorTurkmen, Aydinen_US
dc.contributor.authorAydin, Ali Eminen_US
dc.contributor.authorOguz, Fatma Savranen_US
dc.contributor.authorCarin, Mahmut Nezihen_US
dc.contributor.authorAydin, Filizen_US
dc.date.accessioned2019-06-27T08:01:22Zen_US
dc.date.available2019-06-27T08:01:22Zen_US
dc.date.issued2017en_US
dc.identifier.issn0041-1345en_US
dc.identifier.issn1873-2623en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12469/358en_US
dc.identifier.urihttps://doi.org/10.1016/j.transproceed.2017.01.032en_US
dc.description.abstractIntroduction. High rates of panel-reactive antibody (PRA) may decrease the chance of kidney transplantation and may result in long waiting periods before transplantation. The calculated PRA (cPRA) is performed based on unacceptable HLA antigens. These antigens are identified by a program that was created based on the antibodies that developed against the HLA antigens circulating in serum and on the risk of binding of these antibodies to antigens. The antigen profile of the population and antigen frequencies can be measured and more realistic cPRA positivity rates may be obtained using this method. Materials and Methods. We developed a program based on the HLA antigens of 494 blood donors in 2 European Federation for Immunogenetics accredited Tissue Typing Laboratories in Turkey. Next-generation sequencing based tissue typing (HLA-A -B-C-DR-DQ 4 digits) of the samples was performed. The PRA screening test was performed on 380 patients who were waiting for organ transplant from a cadaver in Istanbul Faculty of Medicine. The single antigen bead assay testing was performed to identify the antibody profiles on 48 hypersensitized patients. Results. The PRA testing results using the current methods were 44.6% +/- 18.5% and the cPRA rate was 86.2% +/- 5.1%. The mean PRA positivity of the sensitized patients using the current methods was 44.6%
dc.description.abstracthowever the rate was 86.2% using the cPRA. Discussion. cPRA shows the rate of the rejected donors according to all unacceptable antigens. The need for a list of unacceptable antigens in place of the PRA positivity rate is a real change in the sensitization-dependent calculation as cPRA positivity rate. Conclusion. In principal implementation of cPRA will encourage many centers and laboratories to adopt a standard measurement of sensitization in Turkey. It will increase the chances of better donor match particularly for hypersensitized patients by the creation of an unacceptable mismatch program using cPRA software.en_US
dc.language.isoEnglishen_US
dc.publisherElsevier Science Incen_US
dc.subjectPRAen_US
dc.subjectHLAen_US
dc.subjectcPRAen_US
dc.subjectCalculated PRAen_US
dc.subjectNext Generation Sequencingen_US
dc.subjectHesaplamalı PRAen_US
dc.subjectYeni Nesil Dizilemeen_US
dc.titleCorrected Panel-Reactive Antibody Positivity Rates for Hypersensitized Patients in Turkish Population With Calculated Panel-Reactive Antibody Softwareen_US
dc.typeArticleen_US
dc.identifier.startpage445en_US
dc.identifier.endpage447en_US
dc.relation.journalTransplantation Proceedingsen_US
dc.identifier.issue3en_US
dc.identifier.volume49en_US
dc.identifier.wosWOS:000398017900013en_US
dc.identifier.doi10.1016/j.transproceed.2017.01.032en_US
dc.contributor.khasauthorYelekçi, Kemalen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record